Hyderabad-based Natco Pharma has filed a lawsuit against Danish drugmaker Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy (semaglutide), before the Delhi High Court.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low.

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

(CNN)– Patients in the U.S. can now get Ozempic for half the price, if they pay in cash. Novo Nordisk, the maker of the diabetes drug announced Monday, Aug. 19, that U.S. patients can now get a ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.